Featured Publications
Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous lupus erythematosusDevelopment of CLEDisease pathogenesisAdaptive immune componentsClinical trial landscapeUnmet medical needFuture therapeutic strategiesPromising clinical trialsFuture pathogenesisLupus erythematosusSignificant morbidityAutoimmune diseasesImmune cellsClinical trialsCurrent treatmentTrial landscapeImmune componentsTherapeutic strategiesDrug AdministrationMedical needDiseasePathogenesisEnvironmental triggersTherapyType I
2020
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.
Vesely MD. Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. The Yale Journal Of Biology And Medicine 2020, 93: 197-206. PMID: 32226348, PMCID: PMC7087062.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous autoimmune diseasesAutoimmune diseasesCutaneous autoimmunityImmune systemEffector armT cellsTherapeutic strategiesChimeric autoantibody receptor T cellsRegulatory armLow-dose interleukin-2Regulatory T cellsExcessive immune activationReceptor T cellsGreater treatment efficacyBroad immunosuppressantsCytokine blockadeTolerogenic vaccinesCostimulatory blockadeDisease remissionImmune activationInflammatory pathwaysImmune homeostasisInterleukin-2Treatment efficacyNormal skin